Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ambenonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.97 |
| ▸ | BCHE | P06276 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.43 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.43 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.43 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ambenonium SCHEMBL5060921 | 0.99 | CHRM2 (0.94) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 | |
| Ambenonium SCHEMBL284678 | 0.99 | CHRM2 (1.00) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 | |
| SCHEMBL11946692 | 0.92 | CHRM2 (0.87) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 | |
| SCHEMBL12648551 | 0.81 | CYP2D6 (0.70) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 | |
| Hydrochloric Acid SCHEMBL8615986 | 0.79 | CYP2D6 (0.61) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 | |
| SCHEMBL212194 | 0.78 | CYP2D6 (0.63) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 | |
| SCHEMBL3557341 | 0.69 | CHRM2 (0.54) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 | |
| Bromide SCHEMBL29757574 | 0.68 | KCNH2 (0.53) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 | |
| Bromide SCHEMBL30175695 | 0.67 | LMNA (0.55) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 | |
| SCHEMBL16715933 | 0.66 | BCHE (0.53) | CHRM2CYP2D6CHRM1ADRA2CCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 964 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466782-B2 | Arylcyclohexylamine derivatives and process for preparing same | Technische Hochschule Köln (DE) | 2025-11-11 | — | — | US | claimed |
| US-20250205751-A1 | CLEANING BRUSH FOR SEMICONDUCTOR DEVICE AND CLEANING MODULE AND CMP EQUIPMENT AND POST-CMP CLEANING METHOD | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-06-26 | — | — | US | claimed |
| WO-2025067458-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND USE THEREOF | 苏州普乐康医药科技有限公司 | 2025-04-03 | — | — | WO | claimed |
| WO-2025032214-A1 | INDAZOLE COMPOUNDS AND AZAINDAZOLE COMPOUNDS AS INHIBITORS OF RAF KINASES | PIERRE FABRE MEDICAMENT (FR) | 2025-02-13 | — | — | WO | claimed |
| US-12221437-B2 | Bispyranilidenes, dithiobispyranilidenes and diselenobispyranilidene and use thereof | SENORICS GMBH (DE) | 2025-02-11 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20250017942-A1 | Prevention and treatment of osteoarticular diseases by inhibiting acetylcholinesterase | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2025-01-16 | — | — | US | claimed |
| CN-113423430-B | Amatoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2024-12-03 | — | — | CN | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20050026919-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| WO-2004103284-A2 | COMPOSITIONS OF A BENZENESULFONAMIDE OR METHYLSULFONYLBENZENE CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CHOLINERGIC AGENT FOR THE TREATMENT OF REDUCED BLOOD FLOW OR TRAUMA TO THE CENTRAL NERVOUS SYSTEM | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | claimed |
| WO-2004103300-A2 | COMPOSITIONS AND METHODS OF TREATING REDUCED BLOOD FLOW TO THE CNS WITH COX-2 INHIBITORS AND CHOLINERGIC AGENTS | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | claimed |
| WO-2004103286-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CHOLIMERGIC AGENT | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | claimed |
| WO-2004103357-A1 | COMPOSITIONS FOR THE TREATMENT OF REDUCED BLOOD FLOW | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0140434-A2 | Pharmaceutical composition with systemic anticholineesterasic, agonistic-cholinergic and antimuscarinic activity | PRODOTTI FORMENTI S.r.l. (IT) | 1985-05-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017942-A1 | Prevention and treatment of osteoarticular diseases by inhibiting acetylcholinesterase | ACHE, BCHE, CHAT | ACHE 1/4885CHRM2 46/4885CYP2D6 588/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | ACHE 2/4885CHRM2 158/4885CYP2D6 2294/4885 |
| US-12466782-B2 | Arylcyclohexylamine derivatives and process for preparing same | DDC, AADAT, SNCA | ACHE 103/4885CHRM2 198/4885CYP2D6 68/4885 |
| US-12221437-B2 | Bispyranilidenes, dithiobispyranilidenes and diselenobispyranilidene and use thereof | PIN1, QDPR, DHPS | ACHE 4097/4885CHRM2 4550/4885CYP2D6 322/4885 |
| US-20050026919-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | ACHE, PTGER2, PTGS2 | ACHE 1/4885CHRM2 11/4885CYP2D6 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.